Disitamab vedotin is an anti‑HER2 monoclonal antibody linked via a cleavable linker to the microtubule inhibitor MMAE. Upon binding HER2 on tumor cells, the ADC is internalized and the linker is proteolytically cleaved in lysosomes to release MMAE, which disrupts tubulin polymerization, causing G2/M mitotic arrest and apoptosis; the membrane‑permeable payload can mediate bystander killing, with potential additional Fc‑mediated effector activity.